Brand and Other Names:Rescriptor
- Classes: HIV, NNRTIs
Dosing & Uses
Dosage Forms & Strengths
400 mg PO TID with other antiretrovirals
- Add 100 mg-tablets (4 tablets totaling 400 mg) in at least 3 oz water; allow to stand for few minutes
- Do NOT use 200 mg tablets (not well-dispersed in water)
- Stir slurry until mixed uniformly; consume promptly
- Rinse glass with water and swallow entire contents of rinse
Used in combination with at least 2 other antiretroviral agents
<16 years old: Safety and efficacy not established
Serious - Use Alternative
Significant - Monitor Closely
Black Box Warnings
Indicated for use only in combination with appropriate antiretroviral drugs
Resistant virus emerges rapidly when delavirdine is administered as monotherapy
Coadministration with drugs highly dependent on CYP3A4 for clearance and those for which elevated plasma levels are associated with serious or life-threatening events (eg, dihydroergotamine, ergonovine, ergotamine, methylergonovine, cisapride, pimozide, alprazolam, midazolam, triazolam)
Coadministration with drugs (eg, CYP inducers) where significant decreases in delavirdine plasma concentrations may occur, which may result in loss of virologic response and possible resistance and cross-resistance to other NNRTIs
Use only in combination with other agents - delavirdine alone results in rapid resistance
Patients with achlorhydria should take with acidic juice
Avoid antacids 1 hr prior to and after administration
Discontinue if severe rash or rash with associated mucocutaneous lesions; erythema multiforme and Stevens-Johnson Syndrome
Avoid St John's wort: may result in loss of virologic response/resistance
Risk of cross resistance to other NNRTI
Risk of immune reconstitution syndrome if used in combination with other antiretroviral drugs
Pregnancy & Lactation
Pregnancy Category: C
Lactation: Not known whether distributed into milk. Because of both the potential for HIV transmission and the potential for serious adverse reactions in nursing infants, mothers should be instructed not to breastfeed.
Health professionals should contact the antiretroviral pregnancy registry to monitor outcomes of pregnant women exposed to delavirdine or other antiretroviral medications by calling 1-800-258-4263 or going to www.APRegistry.com.
A:Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.
B:May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk.
C:Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done.
D:Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk.
X:Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist.
NA:Information not available.
Distribution: low concentration in saliva & semen; CSF 0.4% concurrent plasma concentration
Protein Bound: ~98%, primarily albumin
Bioavailability: 85%; ~20% incr w/ slurry
Half-life: 5.8 hr (mean)
Peak Plasma Time: 1 hr
Metabolism: hepatic via CYP3A4 & 2D6
Excretion: urine (51%, <5% as unchanged drug); feces (44%)
Mechanism of Action
Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI) of HIV-1
Directly binds to reverse transcriptase and inhibits RNA- & DNA-dependent DNA polymerase
To view formulary information first create a list of plans. Your list will be saved and can be edited at any time.
Adding plans allows you to:
- View the formulary and any restrictions for each plan.
- Manage and view all your plans together – even plans in different states.
- Compare formulary status to other drugs in the same class.
- Access your plan list on any device – mobile or desktop.
The above information is provided for general informational and educational purposes only. Individual plans may vary and formulary information changes. Contact the applicable plan provider for the most current information.
|1||This drug is available at the lowest co-pay. Most commonly, these are generic drugs.|
|2||This drug is available at a middle level co-pay. Most commonly, these are "preferred" (on formulary) brand drugs.|
|3||This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs.|
|4||This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.|
|5||This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.|
|6||This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.|
|NC||NOT COVERED – Drugs that are not covered by the plan.|
Drugs that require prior authorization. This restriction requires that specific clinical criteria be met prior to the approval of the prescription.
Drugs that have quantity limits associated with each prescription. This restriction typically limits the quantity of the drug that will be covered.
Drugs that have step therapy associated with each prescription. This restriction typically requires that certain criteria be met prior to approval for the prescription.
Drugs that have restrictions other than prior authorization, quantity limits, and step therapy associated with each prescription.
Select a box to add or remove a plan.
Select a class to view formulary status for similar drugs